N umerous parameters are capable of predicting prognosis in patients with chronic heart failure (CHF). Many of the modern parameters are only assessed by using research tests that are not widely available. There is a need for simple parameters that can be measured anywhere at low cost. Very few attempts have been made to develop scoring systems to predict prognosis in patients with CHF, 1,2 but these are not simple enough for general application. For prognostication in CHF, the following 3 main areas of relatively independent importance emerge: (1) a hemodynamic factor (for example, left ventricular ejection fraction [LVEF]); (2) the patient's functional status (eg, peak oxygen consumption [V O 2 ]); and (3) a metabolic factor, including the neuroendocrine and immunologic processes. 3 Consequently, we have previously proposed a metabolic, functional, and hemodynamic (MFH) staging system for the assessment of prognosis in CHF. 3 Such a system would depend on a straightforward metabolic marker. We propose that the latter could be serum uric acid (UA) levels.
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In CHF, hyperuricemia (independent of kidney function and diuretic dose) is a marker of impaired oxidative metabolism and hyperinsulinemia, 4 -6 inflammatory cytokine activation, 7 and impaired vascular function. 8, 9 The relationship of UA to kidney function and diuretic dose may additionally increase the value of UA as prognostic marker. In one study, it has been suggested that in CHF, UA levels reflect the degree of circulating xanthine oxidase (XO) activity. 10 The XO system is an important source of oxygen free radicals. 11 Additionally, via degradation of accumulated purines, UA is a general marker of cell death (see Figure 1 ). In CHF, weight loss is linked to impaired survival 12 but also to hyperuricemia. 9 We hypothesized that UA might be a widely available and powerful prognosticator. We also hypothesized that patients with high UA levels and low peak V O 2 and LVEF would have a particularly poor prognosis.
Methods
We assessed the relationship between survival and UA in 112 extensively evaluated patients with CHF who (between April 1992 and August 1997) were prospectively recruited into a long-term metabolic study program (derivation sample). The local ethics committee approved this study. All patients gave informed consent. To validate our results, we used a patient sample comprising all CHF outpatients of our hospital not recruited for the derivation study and in whom UA had been determined as part of routine outpatient procedures between 1992 and January 1999 (nϭ182, validation study). In these patients, we tested the principal results and best cutoff values as derived from the derivation study. In these patients, we recorded the results of treadmill exercise testing and radionuclide ventriculography if these had been performed within 4 months of the UA assessment, provided patients had been clinically stable and not hospitalized.
In 194 patients (from both studies), we were able to calculate post hoc the 7-parameter heart failure survival score (HFSS) 1 and compared its prognostic value with that of UA. Finally, we aimed to document the survival of patients with CHF in relation to a 3 risk factor model, comprised of 3 parameters: a high UA level (cutoff from the derivation sample) as marker of metabolic status (M), a marker of low functional capacity (peak V O 2 Յ14 mL/kg per minute 13 ) (F), and a marker of poor cardiac function (LVEF Յ25% 14 ) (H).
In all patients, CHF was diagnosed on the basis of standard criteria, and evidence of left ventricular enlargement or systolic functional impairment by radionuclide ventriculography, chest x-ray, or echocardiography was present (Table 1) . Patients with chronic lung disease, myocardial infarction (within 12 weeks), or severe renal failure were excluded. All patients were treated as clinically indicated with angiotensin-converting enzyme inhibitors (85%), diuretics (89%; spironolactone, 7%), digitalis (24%), nitrates (24%), calcium antagonists (11%), aspirin (9%), warfarin (17%), and ␤-blockers (6%) in varying combinations (derivation versus validation study, PϾ0.05; on allopurinol, none). Venous blood samples (10 mL) were taken after Ն10 minutes of rest in a semirecumbent position for assessment of UA (uricase-peroxidase method, unit for UA: mol/L; 59.48 mol/Lϭ1 mg/dLϭ1 mg %) and other parameters.
Follow-Up
Follow-up for survival (as of September 10, 2001 ) was available in February 2002 from the Office of National Statistics, where all patients had been flagged for reports of death. The study focused on all-cause mortality. Major events included heart transplantation (5 patients, 2 died, 3 still alive) or implantation of a permanent ventricular assist device (1 patient, subsequently died). Patients were censored alive at the time of these events.
MFH Score and Transplantation Evaluation
We retrospectively analyzed 120 consecutive patients (without major contraindications for heart transplantation) who underwent full assessment for heart transplantation eligibility in the German Heart Institute in Berlin between January and June 1999. In all patients, the MFH score was calculated retrospectively on the basis of results that were determined during the patients' transplantation evaluation visit. At the time the responsible physicians had access to these individual results, but they were not aware of the MFH score or of our data on UA and prognosis.
Statistics
All results are presented as meanϮSD. Group differences were assessed by unpaired Student's t tests. Cox proportional hazard analysis was used to assess the association between variables and mortality. Hazard ratio (RR) and 95% confidence interval (CI) for risk factors and significance levels for 2 (likelihood ratio test) are given. Kaplan-Meier cumulative survival plots were constructed (StatView 4.5, Abacus Concepts). Because we considered sensitivity and specificity of equal importance, in ROC analyses, the best prognosticators for survival status were considered to be those parameters that gave the highest product of sensitivity and specificity for predicting death at the respective times. 15 
Results

Derivation Study
The range of observed UA levels was between 187 and 930 mol/L (UA Ͻ400 mol/L; nϭ34 [30%]). During follow-up Figure 1 . The interrelationship between hyperuricemia, XO, cell metabolism and insulin resistance (IR), tissue hypoxia, vascular dysfunction, cytokines, and oxygen free radicals in CHF. Feedback mechanisms cause increased XO activation and hence hyperuricemia. These complex interrelated mechanisms explain why UA levels are correlated with many different parameters and can serve as a metabolic marker with strong prognostic power. IR and tissue wasting (cell death) can cause accumulation of purine bodies and hence hyperuricemia. Increased activation of XO can be caused by tissue hypoxia, which itself is a consequence of vascular (and cardiac) dysfunction. Oxygen free radicals and inflammatory cytokines contribute to vascular dysfunction. Oxygen free radicals promote production of inflammatory cytokines and are themselves produced by XO. Impaired kidney function and diuretic treatment can also contribute to hyperuricemia. PPP indicates pentose phosphate pathway; PPRP, phosphoribosylpyrophosphate. 
Validation Study
These 182 outpatients were older than the derivation study patients, and they had a somewhat better LVEF ( 
Graded Relation Between UA and Survival
Considering all 294 patients with CHF, we found a graded relationship between serum UA and mortality in CHF 
Uric Acid, HFSS Score, and MFH Score
In 194 patients, data were available to calculate the 7-parameter HFSS score (mean, 8.56Ϯ1.24; see the online Data Supplement). The HFSS score had prognostic power at its 3 risk levels 1 ( 2 ϭ39.1, PϽ0.0001) and as continuous variable ( 2 ϭ45.4, PϽ0.0001), which was similar to that of UA in these patients ( 2 ϭ54.0, PϽ0.0001). Both HFSS and UA predicted prognosis independently of each other, regardless of whether the parameters were treated as continuous or categorical variables (all PϽ0.0001). There was a continuous relationship between the estimated probability of death within 1 year and UA levels within each of the HFSS strata ( Figure  4A ). Applying the best UA cutoff (Ն565 mol/L) to the HFSS subgrouping improved the positive and negative discriminatory power for survival prediction in all HFSS strata ( Figure 4B) . The relationship between MFH score and survival is shown in Figure 5 .
MFH Staging and Heart Transplantation (German Heart Institute Berlin)
The MFH score was determined in 120 patients with CHF (female, 15) with the following clinical characteristics: age 53Ϯ8 years, NYHA class 2.5Ϯ0.7, treadmill peak V O 2 14.3Ϯ4.4 mL/kg per minute, LVEF 23Ϯ8%, and UA 469Ϯ145 mol/L. Of 20 patients with MFH score 0 and 35 patients with MFH score 1, none was listed for heart transplantation. Of 47 patients with MFH score 2, 24 patients (51%) were listed, whereas 16 of 18 patients with MFH score 3 (89%) were listed for heart transplantation. The positive predictive value of not being listed for heart transplantation with MFH score 0 or 1 was 100%. By the end of 1999, of 40 patients listed for transplantation, 8 patients (20%) had been transplanted, 3 patients (7.5%) had received a ventricular assist device, and 13 patients (32%) had died. 
Discussion
This study documents and validates that high serum UA levels are a strong, independent marker of impaired prognosis in patients with moderate to severe CHF. The relationship between serum UA and survival in CHF is graded. The assessment of UA provides information independently of and better than other well-established parameters, such as the clinical status, exercise capacity, and parameters of kidney function. In CHF, individualized treatment is needed to achieve optimal outcome. This requires reliable assessment of individual prognosis. One prognostic stratification system has previously been validated (the 7-parameter HFSS score 1 ). This computer-based system may not be simple enough for routine application. We have now shown that UA predicts prognosis as well as and independently of the HFSS score. Adding UA to the HFSS score improves its prognostic power. We suggest in the light of its wide availability and very low cost that UA determination should be considered a routine measurement in the assessment and follow-up for patients with heart failure.
Hyperuricemia has been suggested to reflect raised XO activity in CHF. 10 The XO enzyme system is an important source of oxygen free radicals. 11 The latter provides the pathophysiological link of UA with a large variety of detrimental processes, including increased cytokine production, cell apoptosis, and endothelial dysfunction. In a prospective series of studies on patients with CHF, we have previously shown that hyperuricemia relates to many of these abnormalities 6 -9 independently of diuretic treatment and markers of kidney function. Therefore, serum UA may be a valid metabolic marker in CHF.
The activity of XO within the myocardium is discussed controversially. A significant source of confusion is the large interspecies variability in tissue expression of XO. 16 . For example, myocardial XO enzyme activity was found high in the dog 17 and rat 18 but low in the rabbit 19 and pig. 20 In humans, studies report myocardial XO activity to be either high, 21 low, 22 or undetectable. 23, 24 Although there is some considerable evidence that suggests that the enzyme XO may indeed be expressed in the human myocardium, [25] [26] [27] we believe that the effect may be local. No systemic effects from the myocardial activity of XO have been reported.
We propose to apply MFH assessments for staging of patients with CHF. It is widely accepted that an exercise test with gas exchange analysis is ideal to assess functional capacity of patients with CHF objectively. 28 When the main result of this test (peak V O 2 Ͻ14 mL/kg per minute; yes or no) was complemented with the results of LVEF assessments (Յ25%; yes or no) and a simple blood test (UA Ն565 mol/L [9.50 mg/dL]; yes or no), we were able to distinguish 4 risk groups, ranging from very low mortality (MFH 0, 9% at 3 years) to extremely high mortality (MFH 3, 87.5% at 18 months). It appears logical that these patient groups may need different follow-up strategies. MFH staging may be helpful to guide in the decision of whether to transfer a patient to a heart transplantation center.
The application of our staging system needs to be additionally investigated. Peak V O 2 may be replaceable by simpler measures, such as the 6-minute walk distance. Equally, some might want to use higher LVEF cutoffs or replace LVEF with brain natriuretic peptide levels. The ultimate validation would be to test whether tailoring treatment with this (or any) staging system would improve morbidity and mortality compared with a scenario in which treatment is individualized but formal staging is not used. The role of a genetic predisposition as a potential fourth prognostic factor needs to be assessed in the future, but it is conceivable that the genetic status is already reflected in one of the other factors.
Whether UA could be used to diagnose heart failure or to predict the mode of death is not known. We suggest that UA could be used to monitor metabolic status in CHF and hence to monitor CHF therapy concerning metabolic effects. It has been shown that hyperuricemia in the general population is independently associated with all-cause, total cardiovascular, and ischemic heart disease mortality. 29 Therefore, assessing UA may be of general value in health and illness. 
